TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
31.15
+0.83 (2.74%)
At close: Nov 20, 2024, 4:00 PM
31.86
+0.71 (2.28%)
Pre-market: Nov 21, 2024, 7:21 AM EST
TG Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 264.79 | 233.66 | 2.79 | 6.69 | 0.15 | 0.15 | Upgrade
|
| Revenue Growth (YoY) | 39.53% | 8290.02% | -58.36% | 4300.66% | 0% | 0% | Upgrade
|
| Cost of Revenue | 30.94 | 14.13 | 0.27 | 0.79 | - | - | Upgrade
|
| Gross Profit | 233.85 | 219.53 | 2.52 | 5.9 | 0.15 | 0.15 | Upgrade
|
| Selling, General & Admin | 146.49 | 122.71 | 70.01 | 128.09 | 107.85 | 15.03 | Upgrade
|
| Research & Development | 87.87 | 76.19 | 125.35 | 222.58 | 165.9 | 154.18 | Upgrade
|
| Operating Expenses | 234.35 | 198.9 | 195.36 | 350.67 | 273.75 | 169.21 | Upgrade
|
| Operating Income | -0.51 | 20.63 | -192.84 | -344.77 | -273.59 | -169.06 | Upgrade
|
| Interest Expense | -19.4 | -12.62 | -10.19 | -5.64 | -6.33 | -5.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.02 | 5.04 | 4.7 | 2.31 | 0.54 | 1.47 | Upgrade
|
| EBT Excluding Unusual Items | -13.89 | 13.06 | -198.34 | -348.1 | -279.38 | -172.87 | Upgrade
|
| Pretax Income | -13.89 | 13.06 | -198.34 | -348.1 | -279.38 | -172.87 | Upgrade
|
| Income Tax Expense | 0.48 | 0.39 | - | - | - | - | Upgrade
|
| Net Income | -14.36 | 12.67 | -198.34 | -348.1 | -279.38 | -172.87 | Upgrade
|
| Net Income to Common | -14.36 | 12.67 | -198.34 | -348.1 | -279.38 | -172.87 | Upgrade
|
| Shares Outstanding (Basic) | 145 | 142 | 135 | 132 | 115 | 88 | Upgrade
|
| Shares Outstanding (Diluted) | 145 | 149 | 135 | 132 | 115 | 88 | Upgrade
|
| Shares Change (YoY) | 3.08% | 9.67% | 2.41% | 14.64% | 30.51% | 17.10% | Upgrade
|
| EPS (Basic) | -0.10 | 0.09 | -1.46 | -2.63 | -2.42 | -1.96 | Upgrade
|
| EPS (Diluted) | -0.10 | 0.09 | -1.46 | -2.63 | -2.42 | -1.96 | Upgrade
|
| Free Cash Flow | -28.11 | -31.41 | -176.18 | -296.04 | -214.86 | -132.94 | Upgrade
|
| Free Cash Flow Per Share | -0.19 | -0.21 | -1.30 | -2.24 | -1.86 | -1.50 | Upgrade
|
| Gross Margin | 88.31% | 93.95% | 90.48% | 88.19% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -0.19% | 8.83% | -6924.20% | -5154.28% | -179996.05% | -111220.39% | Upgrade
|
| Profit Margin | -5.42% | 5.42% | -7121.54% | -5204.08% | -183803.29% | -113730.92% | Upgrade
|
| Free Cash Flow Margin | -10.62% | -13.44% | -6326.18% | -4425.70% | -141357.89% | -87458.55% | Upgrade
|
| EBITDA | -0.41 | 20.84 | -192.54 | -344.49 | -273.44 | -168.96 | Upgrade
|
| EBITDA Margin | -0.15% | 8.92% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.1 | 0.21 | 0.3 | 0.28 | 0.16 | 0.1 | Upgrade
|
| EBIT | -0.51 | 20.63 | -192.84 | -344.77 | -273.59 | -169.06 | Upgrade
|
| EBIT Margin | -0.19% | 8.83% | - | - | - | - | Upgrade
|
| Effective Tax Rate | - | 2.99% | - | - | - | - | Upgrade
|
| Revenue as Reported | 264.79 | 233.66 | 2.79 | 6.69 | 0.15 | 0.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.